康方生物PD1单抗获FDA突破性疗法资格,三线治疗转移性鼻咽癌

医药魔方
30 Mar 2021

原标题:康方生物PD1单抗获FDA突破性疗法资格,三线治疗转移性鼻咽癌 来源:医药魔方3月30日,康方生物宣布FDA授予派安普利单抗突破性疗法资格,用于三线治疗转移性鼻咽癌。此前,FDA已经授予过派安普利单抗三线治疗转移性鼻咽癌快速审批通道和孤儿药资格。康方生物曾于2020年9月宣布派安普利单抗三线治疗转移性鼻咽癌的注册性临床试验达到了由独立影像评估的客观缓解率(ORR)主要终点,在既往经过多线...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10